{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-000752","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.776898+00:00","generated_at":"2026-06-07T03:39:01.408680+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Perspective Therapeutics licenses Mayo Clinic's PSMA Alpha-PET platform for up to $68M milestones","bullets":["Upfront cash payment of $1M due within 60 days of Dec 22, 2023; milestone payments up to $68M tied to clinical, regulatory, and commercialization achievements.","Single-digit royalties on net sales of certain Licensed Product components; 40% of any PRV sale proceeds to be shared with Mayo.","Platform uses 64/67 Cu and 203/212 Pb double chelator design for PET imaging and alpha/beta-particle targeted RPT.","Preclinical data showed favorable salivary gland uptake and kidney clearance vs. comparators; initial focus on PSMA-expressing prostate cancer.","Mayo Clinic holds financial interest in the technology; Perspective must use commercially reasonable efforts to bring Licensed Products to market."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-000752","json":"https://secwatch.observer/filing/0001437749-24-000752.json","markdown":"https://secwatch.observer/filing/0001437749-24-000752.md","text":"https://secwatch.observer/filing/0001437749-24-000752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774924000752/0001437749-24-000752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774924000752/isr20240104_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:39:01.408680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1566e25721add26966c8ffc554a8f610f6bc276","claim":"Perspective Therapeutics, Inc. entered into Exclusive Patent License Agreement with Mayo Foundation for Medical Education and Research valued at upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s (effective 2023-12-31).","evidence_excerpt":"On December 31, 2023, Perspective Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an exclusive patent license agreement (the “ License Agreement ”) with the Mayo Foundation for Medical Education and Research (“ Mayo Clinic ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774924000752/0001437749-24-000752-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Mayo Foundation for Medical Education and Research"},{"label":"Value","value":"upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s"},{"label":"Effective","value":"2023-12-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}